NasdaqCM:CORTPharmaceuticals
Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics (CORT)
Wolfe Research recently initiated coverage on Corcept Therapeutics with a Peerperform rating, highlighting both the company’s ongoing patent litigation and antitrust concerns, as well as the potential upside from its drug candidate relacorilant ahead of its upcoming PDUFA date for hypercortisolism on December 30, 2025.
Although Corcept outperformed expectations for earnings per share in the third quarter of 2025, it reported revenue below analyst forecasts, contributing to investor caution...